AI assistant
DIMERIX LIMITED — Capital/Financing Update 2012
Dec 11, 2012
64804_rns_2012-12-11_8b6f80e8-a656-4e66-93a2-9a45c9994737.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [234 x 86] intentionally omitted <==
ASX Company Announcement
12 December 2012
Non-Renounceable Rights Issue Closes
The Directors of Sun Biomedical Limited (ASX:SBN) are pleased to announce that the Company’s non-renounceable, fully underwritten Rights Issue has closed with the results below:
| No. of shares | Amount | |
|---|---|---|
| New shares offered under the Rights | 165,570,004 | $1,158,990.03 |
| Issue | ||
| Total entitlement acceptances | 34,203,174 | $239,422.22 |
| Total shortfall | 131,366,830 | $919,567.81 |
An Appendix 3B will be released following allotment of shares. Allotment of entitlement acceptance shares is scheduled to take place on 14 December 2012 with dispatch of confirmation statements scheduled for 17 December 2012.
The 131,366,830 shortfall shares will be allocated and allotted at the discretion of CPS Securities[1] as per the Underwriting Agreement at $0.007 per share.
Yours faithfully,
==> picture [121 x 51] intentionally omitted <==
Terry Cuthbertson Chairman
1 Cunningham Peterson Sharbanee Securities Pty Ltd
Sun Biomedical Investor Communications Limited Computershare T: +61 1300 850 505 | F: +61 3 9473 2500 ABN 18 001 285 230
ASX:SBN www.sunbiomed.com